The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers

Biotherapy. 1993;6(1):41-9. doi: 10.1007/BF01877385.

Abstract

Twenty-four patients with liver metastases from gastric or colorectal cancer were treated with OK-432-combined adoptive immunotherapy (AIT). Lymphocytes isolated from regional lymph nodes or peripheral blood were cultured with medium containing T cell growth factor and sonicated tumor extract antigen (SE-Ag) for 9-13 days. The cultured lymphocytes were transferred mainly through the hepatic artery after the administration of OK-432, a streptococcal preparation. Sixteen of the 24 patients received a low dose of anti-cancer agents between the OK-432 injection and cell transfer. When cultured without SE-Ag, regional lymph node lymphocytes (RLNL) showed significantly (P < 0.05) higher cytotoxic activity against autologous tumor cells and, on the contrary, lower cytotoxic activity against K562 than peripheral blood lymphocytes (PBL). When cultured with SE-Ag, cytotoxicity of RLNL against autologous tumor cells was nearly equivalent to that of PBL. The blastogenesis of fresh PBL to SE-Ag was significantly (P < 0.05) augmented after the OK-432-combined AIT. Two patients showed complete response and 4 patients showed partial response among 19 patients who had evaluable lesions. Five patients whose liver metastases were resected were treated with OK-432-combined AIT as an adjuvant therapy. To date they are alive without recurrence in the liver.

MeSH terms

  • Adult
  • Aged
  • Antigens, Neoplasm / pharmacology
  • Colorectal Neoplasms / complications*
  • Female
  • Humans
  • Immunotherapy, Adoptive* / adverse effects
  • Interleukin-2 / therapeutic use
  • Liver Neoplasms / immunology*
  • Liver Neoplasms / secondary
  • Liver Neoplasms / therapy*
  • Lymphocyte Activation / drug effects
  • Male
  • Middle Aged
  • Picibanil / adverse effects
  • Picibanil / therapeutic use*
  • Stomach Neoplasms / complications*

Substances

  • Antigens, Neoplasm
  • Interleukin-2
  • Picibanil